Response and Toxicity
| Patient No. . | Dose Level* . | Response (6 weeks) . | Therapy After 6-Week Evaluation . | Response to Subsequent Therapy . | Status (6 months) . | Current Status (Survival) in Days . |
|---|---|---|---|---|---|---|
| 1 | 1 | PD | Oral etoposide (8 courses) | VGPR | Well VGPR | DOD (350) |
| 2 | 1 | SD | Oral etoposide (12 doses) | VGPR | Well VGPR | AWD (485) |
| 3 | 1 | PD | None | PD | DOD | (94) |
| 4 | 2 | SD | Oral etoposide (3 courses) | CCR | CCR | CCR (319+) |
| 5 | 2 | MR | MIBG-radionucleide | SD | Well SD | DOD (222) |
| 6 | 2 | PD | Phenybuteral CPT11 | PD | AWD | AWD (283+) |
| 7 | 3 | PR | None | — | Well PR | AWD (300+) |
| 8 | 3 | SD | None | — | CCR | CCR (180+) |
| 9 | 3 | PD | Oral etoposide (1 course) | SD | TE | AWD (171) |
| 10 | 3 | SD | None | — | TE | AWD (150+) |
| Patient No. . | Dose Level* . | Response (6 weeks) . | Therapy After 6-Week Evaluation . | Response to Subsequent Therapy . | Status (6 months) . | Current Status (Survival) in Days . |
|---|---|---|---|---|---|---|
| 1 | 1 | PD | Oral etoposide (8 courses) | VGPR | Well VGPR | DOD (350) |
| 2 | 1 | SD | Oral etoposide (12 doses) | VGPR | Well VGPR | AWD (485) |
| 3 | 1 | PD | None | PD | DOD | (94) |
| 4 | 2 | SD | Oral etoposide (3 courses) | CCR | CCR | CCR (319+) |
| 5 | 2 | MR | MIBG-radionucleide | SD | Well SD | DOD (222) |
| 6 | 2 | PD | Phenybuteral CPT11 | PD | AWD | AWD (283+) |
| 7 | 3 | PR | None | — | Well PR | AWD (300+) |
| 8 | 3 | SD | None | — | CCR | CCR (180+) |
| 9 | 3 | PD | Oral etoposide (1 course) | SD | TE | AWD (171) |
| 10 | 3 | SD | None | — | TE | AWD (150+) |
For definition of responses see text: Patients 2, 4, 7, 8, 10 were considered to have a response or disease stability after the tumor immunogen alone.
Abbreviations: PD, progressive disease; SD, stable disease; MR, mixed response; PR, partial response; VGPR, very good partial response; DOD, died of disease; AWD, alive with disease; TE, too early.
For cells given at each dose level see Materials and Methods.